3-(aminomethyl)-N-methyl-N-[(2R)-1-[methyl-[(2R)-1-oxo-3-phenyl-1-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]propan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]benzamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(aminomethyl)-N-methyl-N-[(2R)-1-[methyl-[(2R)-1-oxo-3-phenyl-1-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]propan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]benzamide
• 化学式: C₄₁H₅₁N₅O₃
• 分子量: 661.888
• InChiKey: SZYAYDXQUKPMLT-LQFQNGICSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  49
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-tert-butoxycarbonyl-N-methyl-D-phenylalanine 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 162.99h， 生成 3-(aminomethyl)-N-methyl-N-[(2R)-1-[methyl-[(2R)-1-oxo-3-phenyl-1-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]propan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]benzamide
  参考文献：
  名称：

  The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency

  摘要：

  in order to obtain more potent growth hormone secretagogues, a comparison of ipamorelin and NN703 suggested the addition of a polar group at the C-terminus of NN703. A study was conducted using constrained amines for this purpose. Here, substituted 4-piperidinylamino- and 4-dimethylaminopiperidino-substitutents were found to give the most active compounds. A replacement of the 4-dimethylaminopiperidino-substituent with 4-hydroxypiperidino resulted in a series of compounds, which showed in vitro activity with EC50 values in the low nanomolar range, and favourable kinetic properties, such as 40% oral bioavailability. The most promising compound was also tested in a swine in vivo model, resulting in a growth hormone level with a C-max of over 40 ng mL(-1). (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved..

  DOI：

  10.1016/s0223-5234(02)01370-3

文献信息

• [EN] COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES<br/>[FR] COMPOSES A PROPRIETES DE LIBERATION DE L'HORMONE DE CROISSANCE
  申请人：NOVO NORDISK AS

  公开号：WO2000001726A1

  公开（公告）日：2000-01-13

  The invention relates to novel compounds, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone.

  该发明涉及新型化合物、含有它们的组合物以及它们用于治疗由生长激素缺乏引起的医疗障碍的用途。
• Compounds with growth hormone releasing properties
  申请人：Peschke Bernd

  公开号：US20050233981A1

  公开（公告）日：2005-10-20

  Disclosed are compounds of formula I wherein R 1 , R 2 , R 5 , R 6 , R 7 , R 8 , G, J, L, M, a, b, c, d, e, and f are as defined in the specification, and compositions containing them. These compounds are useful for treating medical disorders resulting from a deficiency in growth hormone.

  本发明涉及一种公式I的化合物，其中R1、R2、R5、R6、R7、R8、G、J、L、M、a、b、c、d、e和f如规范中所定义，以及含有它们的组合物。这些化合物可用于治疗因生长激素缺乏引起的医学疾病。
• COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES
  申请人：NOVO NORDISK A/S

  公开号：EP1100824A1

  公开（公告）日：2001-05-23
• METHODS OF TREATING OR PREVENTING EMESIS USING GROWTH HORMONE SECRETAGOGUES
  申请人：Helsinn Therapeutics (U.S.), Inc.

  公开号：EP2146732A1

  公开（公告）日：2010-01-27
• Method of reducing C-reactive protein using growth hormone secretagogues
  申请人：Polvino J. William

  公开号：US20050261201A1

  公开（公告）日：2005-11-24

  The present invention relates to a method of reducing C-reactive protein in a subject in need of treatment thereof, wherein the subject is at risk of having or the subject has already had a vascular event or suffering from an inflammatory disease or disorder. In one embodiment, the vascular event is a cardiovascular event (e.g., myocardial infarction). In another embodiment, the vascular event is a cerebrovascular event (e.g., stroke (such as transient ischemic attacks (TIAs)). In yet another embodiment the vascular event is a peripheral vascular event (e.g., intermittent claudication). The method comprises administering a therapeutically effective amount of at least one growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be coadministered with a second growth hormone secretagogue, HMG CoA reductase inhibitor, an ACAT inhibitor, a CETP inhibitor, an anti-inflammatory agent, an ACE inhibitor, a Beta blocker, a cholesterol absorption inhibitor, a nicotonic acid, a fibric acid derivative, a bile acid sequestering agent or a combination thereof.